Edition:
United States

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

29.50USD
19 Jan 2018
Change (% chg)

$2.00 (+7.27%)
Prev Close
$27.50
Open
$29.05
Day's High
$29.85
Day's Low
$28.38
Volume
302,050
Avg. Vol
106,012
52-wk High
$30.85
52-wk Low
$11.80

Select another date:

Wed, Jan 10 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

BRIEF-Atara Biotherapeutics reports Q3 loss per share $1.02

* Atara Biotherapeutics Inc announces third quarter 2017 financial results and recent highlights

BRIEF-Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230

* Atara Biotherapeutics receives rare pediatric disease designation from FDA for Ata230 for treatment of congenital cytomegalovirus (CMV) infection Source text for Eikon: Further company coverage:

BRIEF-Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations

* Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations, including updated interim results from a phase 1 study of autologous ATA190 in patients with progressive multiple sclerosis (MS)

BRIEF-Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

* Atara Biotherapeutics Inc - ‍announced receipt of positive regulatory feedback from Health Canada for ATA129​

BRIEF-Atara Biotherapeutics receives FDA orphan drug designation for ATA230

* Atara Biotherapeutics receives FDA orphan drug designation for ata230

Select another date: